Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
The Lancet. Haematology
|
June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Blood
|
January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Blood Advances
|
July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Alison R Walker, Guido Marcucci, Jun Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia
Richard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.
JCO Oncology Practice
|
October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
Anand P Jillella, Martha L Arellano, Manila Gaddh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms
Beata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Blood
|
January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis, Farhad Ravandi, Eunice S Wang, et al.
The Lancet. Oncology
|
August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
The Lancet. Haematology
|
June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Blood
|
January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Blood Advances
|
July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Alison R Walker, Guido Marcucci, Jun Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia
Richard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.
JCO Oncology Practice
|
October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
Anand P Jillella, Martha L Arellano, Manila Gaddh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms
Beata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Blood
|
January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis, Farhad Ravandi, Eunice S Wang, et al.
The Lancet. Oncology
|
August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Page
of 5